Patents by Inventor Michael Briskin

Michael Briskin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-CTHRC1 FUSION PROTEINS AND METHODS OF USING THE SAME
    Publication number: 20250215070
    Abstract: The present invention is directed to anti-CTHRC1 fusion proteins, compositions comprising the same, and methods of using such anti-CTHRC1 fusion proteins and compositions for the prevention and/or treatment of cancer. Wherein anti-CTHRC1 fusion proteins comprise a first domain comprising a CTHRC1 binding moiety; and a second domain comprising a T cell engager; preferably wherein the T cell engager comprises a ligand for a receptor expressed on a T cell.
    Type: Application
    Filed: January 10, 2023
    Publication date: July 3, 2025
    Inventors: Sam Cooper, Christopher Harvey, Michael Briskin
  • ANTI-COLLAGEN TRIPLE HELIX REPEAT CONTAINING 1 (CTHRC1) ANTIBODIES AND METHODS OF USING THE SAME
    Publication number: 20250213710
    Abstract: Collagen Triple Helix Repeat Containing 1 (CTHRC1) was identified from a subtractive hybridization cDNA library, seeking genes associated with repair of arterial injury. The present invention is directed to anti-CTHRC1 antibodies, compositions comprising the same, and methods of using such antibodies and compositions for the prevention, diagnosis and treatment of a disease or disorder, such as, e.g., cancer, bone disease, fibrotic disease, arthritis, and osteoporosis.
    Type: Application
    Filed: January 10, 2023
    Publication date: July 3, 2025
    Inventors: Sam Cooper, Allison Nixon, Max London, Elizabeth Koch, Christopher Harvey, Michael Briskin
  • COMBINATION THERAPY FOR TREATMENT OF TUMORS COMPRISING CANCER-ASSOCIATED FIBROBLASTS
    Publication number: 20250059267
    Abstract: The disclosure provides compositions and methods comprising at least one TGF-0 inhibitor and at least one Activin inhibitor for use in methods of treating CAF-enriched cancers and/or fibrotic disease.
    Type: Application
    Filed: May 13, 2022
    Publication date: February 20, 2025
    Inventors: Sam COOPER, Allison NIXON, Max LONDON, Elizabeth KOCH, Arif JETHA, Christopher HARVEY, Michael BRISKIN
  • COADMINISTRATION OF ALPHA-FETOPROTEIN AND AN IMMUNOMODULATORY AGENT TO TREAT MULTIPLE SCLEROSIS
    Publication number: 20120087934
    Abstract: The present invention features methods for treating multiple sclerosis by administering an alpha-fetoprotein polypeptide (or a biologically active fragment, derivative, or analog thereof) and one or more immunomodulatory agents to a patient in need thereof. Also disclosed are compositions and kits that contain an alpha-fetoprotein polypeptide (or a biologically active fragment, derivative, or analog thereof) and one or more immunomodulatory agents.
    Type: Application
    Filed: December 15, 2011
    Publication date: April 12, 2012
    Applicant: Merrimack Pharmaceuticals, Inc.
    Inventors: Edward J. Stewart, Michael Briskin
  • METHODS OF TREATING MULTIPLE SCLEROSIS BY ADMINISTRATION OF ALPHA-FETOPROTEIN IN COMBINATION WITH AN INTEGRIN ANTAGONIST
    Publication number: 20100150915
    Abstract: The present invention relates to methods for treating multiple sclerosis by administering therapeutically effective amounts of an alpha-fetoprotein polypeptide (or a biologically active fragment, derivative, or analog thereof) and an integrin antagonist (e.g., natalizumab) to a patient in need thereof. Also disclosed are compositions and kits that comprise therapeutically effective amounts of an alpha-fetoprotein polypeptide (or a biologically active fragment, derivative, or analog thereof) and an integrin antagonist (e.g., natalizumab).
    Type: Application
    Filed: February 20, 2008
    Publication date: June 17, 2010
    Inventors: Edward J. Stewart, Michael Briskin
  • COADMINISTRATION OF ALPHA-FETOPROTEIN AND AN IMMUNOMODULATORY AGENT TO TREAT MULTIPLE SCLEROSIS
    Publication number: 20100028297
    Abstract: The present invention features methods for treating multiple sclerosis by administering an alpha-fetoprotein polypeptide (or a biologically active fragment, derivative, or analog thereof) and one or more immunomodulatory agents to a patient in need thereof. Also disclosed are compositions and kits that contain an alpha-fetoprotein polypeptide (or a biologically active fragment, derivative, or analog thereof) and one or more immunomodulatory agents.
    Type: Application
    Filed: December 19, 2007
    Publication date: February 4, 2010
    Inventors: Edward J. Stewart, Michael Briskin
  • Mucosal vascular addressins and uses thereof
    Publication number: 20070178089
    Abstract: The present invention relates to isolated antibodies and antigen-binding fragments that selectively bind human MAdCAM.
    Type: Application
    Filed: April 3, 2007
    Publication date: August 2, 2007
    Inventors: Michael Briskin, Douglas Ringler, Dominic Picarella, Walter Newman
  • Mucosal vascular addressins and uses thereof
    Publication number: 20060057135
    Abstract: The present invention relates to pharmaceutical compositions which comprise an antibody and/or antigen-binding fragments which have the epitopic specificity of ACT-1 monoclonal antibody.
    Type: Application
    Filed: November 1, 2005
    Publication date: March 16, 2006
    Inventors: Michael Briskin, Douglas Ringler, Dominic Picarella, Walter Newman